retatrutide release Subcutaneous Fat Loss Results: What Clinical Trials Reveal About Effectiveness and Safety Retatrutide—A Game Changer in Obesity

Unlike single- or dual-pathway compounds, it is a GIP, GLP-1, and glucagon triple receptor agonist , meaning it simultaneously activates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon

You might notice your blood pressure decreases most significantly in the three days following your injection, or that your fasting glucose is consistently in normal range for the first time in years

Then, your healthcare provider will guide you through the process, advising you when to increase your dose and to what dosage

Additional dual agents that target GLP-1 and GIP include Tirzepatide, which has shown to provide greater glycemic control compared to available single agonist agents

Called Byetta (exenatide) and originally developed by Amylin Pharmaceuticals, the drug was later marketed by AstraZeneca

Why Are GLP-1 and Peptide Therapies Becoming Popular